FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2406396914> ?p ?o ?g. }

• W2406396914 abstract "Background: The need remains for novel agents that prolong survival and/or improve QOL in women with aBC. EP is a long-acting topoisomerase 1 inhibitor engineered to produce sustained exposure to irinotecan and its active metabolite SN38. Given previous efficacy seen in an earlier phase II trial in MBC, EP 145 mg/m2 every 3 weeks was compared to TPC (one of 7 single-agent regimens) in the randomized phase 3 BEACON study (NCT01492101). As reported at ASCO 2015 (abstract 1001), EP prolonged median overall survival by 2.1 months, although this did not reach statistical significance (12.4 vs 10.3 months; HR 0.87, p=0.08). Grade ≥ 3 adverse events were significantly less common with EP (48% vs 63% with TPC, p Methods: Patients completed validated health-related QoL (HRQoL) questionnaires, EORTC QLQ-C30 (version 3.0) and breast cancer-specific QLQ-BR23, pretreatment and every 8 weeks until progression, death or withdrawal of consent. Questionnaires were scored according to the EORTC manual. For each scale, raw scores were standardized via a linear transformation to a range from 0 to 100. Absolute scores and changes from baseline were analyzed longitudinally and categorically using a 5-point difference calculated by treatment group. Comparisons between treatment groups were conducted to evaluate the differences in global health status, functional scores and symptoms over time. Results: The majority of patients who were randomized (total: 733/852 [86%], EP: 378/429 [88%], TPC: 355/423 [84%]) completed at least one post-baseline HRQoL questionnaire. In the EORTC QLQ-C30, grade ≥ 3 AEs significantly impacted HRQoL measured by global health status and 5 additional functional domains. Of the six domains, compared to TPC in a longitudinal analysis, EP was statistically superior in the mean treatment effect through Week 32 in global health status p=0.02 and physical functioning scale p=0.01. EP was also numerically superior in all other scales. In EORTC QLQ-C30 and BR-23, a total of 13 symptoms were measured and categorically analyzed. There were no treatment differences in 7 of 13 symptom scales. EP was associated with worsening of 3 symptom scales: appetite loss, nausea/vomiting, and diarrhea. TPC was associated with worsening of 2 symptom scales: dyspnea and systemic side effects. Conclusions: In the phase 3 BEACON trial comparing EP to TPC, the more favorable toxicity profile of EP resulted in an improvement in global health status and physical function (results of the symptom scales confirmed the different toxicities of the two arms). EP remains a promising investigational therapy for aBC. Citation Format: Cortes J, Awada A, Perez EA, Rugo HS, Twelves C, Im S-A, Zhao C, Hoch U, Ney J, Hannah AL, O9Shaughnessy J. Impact of treatment on quality of life (QOL) in the BEACON study, a randomized phase III trial of etirinotecan pegol (EP) versus treatment of physician9s choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-11-08." @default.
• W2406396914 created "2016-06-24" @default.
• W2406396914 creator A5010064853 @default.
• W2406396914 creator A5020490043 @default.
• W2406396914 creator A5036907815 @default.
• W2406396914 creator A5037359057 @default.
• W2406396914 creator A5037412714 @default.
• W2406396914 creator A5041912334 @default.
• W2406396914 creator A5048570099 @default.
• W2406396914 creator A5048581112 @default.
• W2406396914 creator A5048769980 @default.
• W2406396914 creator A5049358292 @default.
• W2406396914 creator A5053610042 @default.
• W2406396914 date "2016-02-15" @default.
• W2406396914 modified "2023-09-27" @default.
• W2406396914 title "Abstract P4-11-08: Impact of treatment on quality of life (QOL) in the BEACON study, a randomized phase III trial of etirinotecan pegol (EP) versus treatment of physician's choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C)" @default.
• W2406396914 doi "https://doi.org/10.1158/1538-7445.sabcs15-p4-11-08" @default.
• W2406396914 hasPublicationYear "2016" @default.
• W2406396914 type Work @default.
• W2406396914 sameAs 2406396914 @default.
• W2406396914 citedByCount "0" @default.
• W2406396914 crossrefType "proceedings-article" @default.
• W2406396914 hasAuthorship W2406396914A5010064853 @default.
• W2406396914 hasAuthorship W2406396914A5020490043 @default.
• W2406396914 hasAuthorship W2406396914A5036907815 @default.
• W2406396914 hasAuthorship W2406396914A5037359057 @default.
• W2406396914 hasAuthorship W2406396914A5037412714 @default.
• W2406396914 hasAuthorship W2406396914A5041912334 @default.
• W2406396914 hasAuthorship W2406396914A5048570099 @default.
• W2406396914 hasAuthorship W2406396914A5048581112 @default.
• W2406396914 hasAuthorship W2406396914A5048769980 @default.
• W2406396914 hasAuthorship W2406396914A5049358292 @default.
• W2406396914 hasAuthorship W2406396914A5053610042 @default.
• W2406396914 hasConcept C121608353 @default.
• W2406396914 hasConcept C126322002 @default.
• W2406396914 hasConcept C159110408 @default.
• W2406396914 hasConcept C168563851 @default.
• W2406396914 hasConcept C197934379 @default.
• W2406396914 hasConcept C203092338 @default.
• W2406396914 hasConcept C2779951463 @default.
• W2406396914 hasConcept C2780259306 @default.
• W2406396914 hasConcept C526805850 @default.
• W2406396914 hasConcept C530470458 @default.
• W2406396914 hasConcept C65409693 @default.
• W2406396914 hasConcept C71924100 @default.
• W2406396914 hasConceptScore W2406396914C121608353 @default.
• W2406396914 hasConceptScore W2406396914C126322002 @default.
• W2406396914 hasConceptScore W2406396914C159110408 @default.
• W2406396914 hasConceptScore W2406396914C168563851 @default.
• W2406396914 hasConceptScore W2406396914C197934379 @default.
• W2406396914 hasConceptScore W2406396914C203092338 @default.
• W2406396914 hasConceptScore W2406396914C2779951463 @default.
• W2406396914 hasConceptScore W2406396914C2780259306 @default.
• W2406396914 hasConceptScore W2406396914C526805850 @default.
• W2406396914 hasConceptScore W2406396914C530470458 @default.
• W2406396914 hasConceptScore W2406396914C65409693 @default.
• W2406396914 hasConceptScore W2406396914C71924100 @default.
• W2406396914 hasLocation W24063969141 @default.
• W2406396914 hasOpenAccess W2406396914 @default.
• W2406396914 hasPrimaryLocation W24063969141 @default.
• W2406396914 hasRelatedWork W12959130 @default.
• W2406396914 hasRelatedWork W13007109 @default.
• W2406396914 hasRelatedWork W13151608 @default.
• W2406396914 hasRelatedWork W16329433 @default.
• W2406396914 hasRelatedWork W17026572 @default.
• W2406396914 hasRelatedWork W2507035 @default.
• W2406396914 hasRelatedWork W2677511 @default.
• W2406396914 hasRelatedWork W3519569 @default.
• W2406396914 hasRelatedWork W5667359 @default.
• W2406396914 hasRelatedWork W8015672 @default.
• W2406396914 isParatext "false" @default.
• W2406396914 isRetracted "false" @default.
• W2406396914 magId "2406396914" @default.
• W2406396914 workType "article" @default.